Company intelligence / Profile preview

EDI International

Buffalo, New York, United States

Ownership: Private
Development stage: Other

Overview

EDI enables translational drug discovery by supporting academic researchers to bridge the early funding and technical expertise gap ("valley of death"), aiming for licensing or company formation upon proof-of-concept completion. Clinical results not reported as EDI operates pre-clinical incubator programs

Therapeutic areas: Other
Modalities: Small moleculeBiologic
Industry: Investors

Partnerships

University at BuffaloUniversity of RochesterRoswell Park Comprehensive Cancer CenterNovo Nordisk

Beyond the preview

Go deeper on EDI International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDI International.

Explore the full profile